ClinicalTrials.gg
CompletedNCT05288673Updated May 9, 2023Results posted

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

A Phase 1 interventional study of ALXN1210 and Placebo in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 6 years 7 months after the study started (first participant enrolled Jul 2015, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

This study evaluated the safety and tolerability of multiple doses of ALXN1210 (400 and 800 milligrams [mg]) following intravenous (IV) administration to healthy participants.

Read the detailed description

Participants were divided into 2 cohorts and were randomly assigned in a 3:1 ratio to receive IV ALXN1210 or placebo. Participants in Cohort 1 received 5 IV doses of 400 mg of ALXN1210 or placebo administered every 28 days. To determine if dose continuation and dose escalation to Cohort 2 should occur, the Safety Review Committee conducted a blinded review of the available safety data after Day 15 of the second dose of the last participant in Cohort 1. Participants in Cohort 2 received 5 doses of 400 mg of ALXN1210 or placebo and 5 IV doses of 800 mg of ALXN1210 or placebo administered intravenously every 28 days. Safety, PK, PD, and immunogenicity assessments were performed during the Follow-up Period after the last dose.

02

Conditions studied

  • Healthy

Keywords

  • ALXN1210
  • Pharmacokinetics
  • Pharmacodynamics
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants ≥ 25 and ≤ 55 years old; smokers (no more than 10 cigarettes daily), former smokers (at the Investigator's discretion), or nonsmokers.
  • from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
  • (corrected using the Fridericia formula) ≤ 450 milliseconds (ms) for males and ≤ 470 ms for females at Screening and prior to dosing on Day 1.
  • Participant was willing and able to give written and comply with the study visit schedule.
  • Documented vaccination with tetravalent meningococcal conjugate vaccine (MCV4) at least 56 days and not more than 3 years prior to dosing. Documentation must have included a positive serum bactericidal antibody test to confirm an immune response before the study drug administration.
  • Vaccination with serogroup B vaccine at least 56 days prior to dosing on Day 1, with a booster administered at least 28 days prior to dosing on Day 1.
  • Male participants with a female spouse/partner of or a pregnant or breastfeeding spouse or partner were required to use barrier (male condom) during the treatment period and for at least 6 months after the last dose of ALXN1210.

Exclusion criteria

Exclusion Criteria:

  • Participants who had intimate and prolonged contact (defined as living under the same roof or providing personal care) with individuals who were either , or had specific underlying medical conditions (persons with anatomic or functional asplenia [including sickle cell disease]; persons with congenital complement, properdin, factor D, or primary antibody deficiencies, persons with acquired complement deficiencies [for example, those receiving eculizumab], and persons with [HIV]) or with persons younger than 2 years of age or older than 65 years of age
  • Participants who were one of the following: professionals exposed to environments of greater risk for meningococcal disease; research, industrial, and clinical laboratory personnel routinely exposed to Neisseria meningitidis; military personnel during recruit training (military personnel may be at increased risk when accommodated in close quarters); daycare center workers; those living on a college or university campus; or those who planned to travel during the course of the study to or had travelled to endemic areas for meningococcal meningitis (for example, India, Sub-Saharan Africa, pilgrimage to Saudi Arabia for Hajj) within the past 6 months
  • History of any Neisseria infection
  • History of unexplained recurrent infection or infection that required treatment with systemic antibiotics within the last 90 days prior to dosing
  • HIV infection (evidenced by HIV-1 or HIV-2 antibody titer)
  • Acute or chronic virus infection (evidenced by the presence of hepatitis B surface antigen or immunoglobulin M antibodies against hepatitis B core antigen)
  • Acute or chronic virus infection (evidenced by antibody titer)
  • Active systemic viral or fungal infection within 14 days prior to dosing
  • Positive or indeterminate QuantiFERON-TB test indicating possible tuberculosis infection
  • History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to the screening visit
  • Female participants who were breastfeeding or were of , including any female who had experienced menarche and who had not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who was pregnant, breastfeeding, or not .
  • Positive serum pregnancy test at Screening or Day -1
  • Serum creatinine > (ULN) of the reference range of the testing laboratory at Screening or Day -1.
  • or aspartate aminotransferase > ULN of the reference range of the testing laboratory at Screening or > 1.5*ULN of the reference range of the testing laboratory at Day -1.
  • Any of the following hematology results: \< 135 grams (g)/L for males and \< 120 g/L for females; hematocrit \< 0.41 L/L for males and \< 0.36 L/L for females; white blood cells \< 3.5*10\^3/microliter (μL) or > ULN of the testing laboratory reference range; absolute neutrophils \< 1.5*10\^3/μL (\< 1.0*10\^3/μL for black race participants) or > ULN of the testing laboratory reference range; and \< the lower limit of normal of the testing laboratory reference range or > 450*10\^3/μL at Screening or Day -1; or complete blood count clinical laboratory results considered as and unacceptable by the Investigator at Day -1.
  • History of complement deficiency or complement activity below normal reference range as evaluated by complement alternative pathway enzyme-linked immunosorbent assay at Screening.
  • History of , other than basal cell carcinoma that had been treated and had no evidence of recurrence.
  • Participation in a clinical study within 30 days before initiation of dosing on Day 1 or use of any experimental small-molecule therapy within 30 days prior to dosing on Day 1.
  • Participation in more than 1 clinical study of a monoclonal antibody (mAb) or participation in a clinical study of a mAb within the 12 months prior to Screening during which the participant was exposed to the active study drug. Participants who had participated in only 1 study of an mAb were considered for enrollment if they had completed that study more than 12 months prior to Screening.
  • Major surgery or hospitalization within 90 days prior to dosing.
  • to receiving MCV4 and/or serogroup B vaccine, including severe (life-threatening) allergic reaction to a previous dose of MCV4 and/or serogroup B vaccine, severe (life-threatening) allergy to any vaccine component, or previous diagnosis of Guillain-Barré syndrome.
  • History of allergy to of ALXN1210 (that is, polysorbate 80).
  • Documented history of allergy to penicillin or cephalosporin.
  • History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
  • Positive urine drug toxicology screen at Screening or Day -1.
  • Donation of plasma within 7 days prior to dosing. Donation or loss (excluding volume drawn at Screening) of more than 50 mL of blood within 30 days of dosing or more than 499 mL of blood within 56 days of dosing.
  • Use of prescription medications within 28 days prior to study drug administration.
  • Clinical diagnosis of any or rheumatologic disease (for example, systemic lupus erythematosus, rheumatoid arthritis).
  • Immunization with a 1 month prior to dosing or planned vaccination during the course of the study (except for the vaccination planned by the study protocol).
  • Presence of fever (confirmed body temperature > 37.6°C; for example, a fever associated with a symptomatic viral or bacterial infection) within 14 days prior to the first dose.
  • Participants with any medical history, conditions or risks that, in the opinion of the Investigator, would have interfered with the participant's full participation in the study or compliance with the protocol, posed any additional risk for the participant, or confounded the assessment of the participant or outcome of the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ALXN1210 400 mg

    Participants received ALXN1210 every 28 days.

    Drug: ALXN1210

  • Experimental
    ALXN1210: 800 mg

    Participants received ALXN1210 every 28 days.

    Drug: ALXN1210

  • Placebo comparator
    Placebo

    Participants received placebo every 28 days.

    Drug: Placebo

Interventions

  • ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.

    Also known as: Ultomiris, Ravulizumab

  • DrugPlacebo

    Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Day 309

Secondary outcomes

  1. Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210

    Blood samples were collected for estimation of AUCinf by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

    Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309

  2. Area Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210

    Blood samples were collected for estimation of AUCt by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

    Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309

  3. Maximum Observed Serum Concentration (Cmax) of ALXN1210

    Blood samples were collected for estimation of Cmax by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

    Time frame: Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309

  4. Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113

    Blood samples were collected for analysis of free C5 concentration.

    Time frame: Baseline, Day 113

  5. Percent Change From Baseline in Total C5 Concentration at Day 113

    Blood samples were collected for analysis of total C5 concentration.

    Time frame: Baseline, Day 113

  6. Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113

    Blood samples were collected for analysis of cRBC hemolysis.

    Time frame: Baseline, Day 113

  7. Percent Change From Baseline in C5 Activation at Day 113

    Blood samples were collected for analysis of C5 activation. Results are reported as percent change in both the complement classical pathway (CCP) activity response and the complement alternative pathway (CAP) activity response.

    Time frame: Baseline, Day 113

  8. Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210

    Blood samples were collected to evaluate antibody response through development of ADAs.

    Time frame: Baseline up to Day 309

07

Results

Posted May 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Started664
Received at least 1 dose of study drug664
Completed663
Not completed001
Withdrew: Consent withdrawn by subject001

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline up to Day 309
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)664
SecondaryArea Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210

Blood samples were collected for estimation of AUCinf by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

Time frame:
Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Reported as:
Mean · hours*micrograms/milliliter (h*ug/mL)
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210
hours*micrograms/milliliter (h*ug/mL)Cohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mg
Area Under The Serum Concentration Versus Time Curve From Time Zero To Infinity (AUCinf) of ALXN1210209047.941 ± 34101.040489692.330 ± 58968.554
SecondaryArea Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210

Blood samples were collected for estimation of AUCt by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

Time frame:
Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Reported as:
Mean · h*ug/mL
Area Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210
h*ug/mLCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mg
Area Under The Serum Concentration From Time Zero To The Time of The Last Quantifiable Concentration (AUCt) of ALXN1210205241.063 ± 32514.529478063.379 ± 54295.251
SecondaryMaximum Observed Serum Concentration (Cmax) of ALXN1210

Blood samples were collected for estimation of Cmax by noncompartmental analyses using Phoenix WinNonlin 6.3 or higher.

Time frame:
Predose, end of infusion, 30 minutes, 4 hours, 8 hours and 24 hours post start of infusion on Day 1 up to Day 309
Reported as:
Mean · ug/mL
Maximum Observed Serum Concentration (Cmax) of ALXN1210
ug/mLCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mg
Maximum Observed Serum Concentration (Cmax) of ALXN1210210.333 ± 34.869454.400 ± 50.639
SecondaryPercent Change From Baseline in Free Complement Protein C5 Concentration at Day 113

Blood samples were collected for analysis of free C5 concentration.

Time frame:
Baseline, Day 113
Reported as:
Mean · Percent Change
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113
Percent ChangeCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Percent Change From Baseline in Free Complement Protein C5 Concentration at Day 113-31.63 ± 15.484-93.8820 ± 11.2938-22.16 ± 15.965
SecondaryPercent Change From Baseline in Total C5 Concentration at Day 113

Blood samples were collected for analysis of total C5 concentration.

Time frame:
Baseline, Day 113
Reported as:
Mean · Percent Change
Percent Change From Baseline in Total C5 Concentration at Day 113
Percent ChangeCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Percent Change From Baseline in Total C5 Concentration at Day 11342.57 ± 28.445154.36 ± 23.053-8.65 ± 17.351
SecondaryPercent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113

Blood samples were collected for analysis of cRBC hemolysis.

Time frame:
Baseline, Day 113
Reported as:
Mean · Percent Change
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113
Percent ChangeCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis at Day 113-52.53 ± 22.740-77.75 ± 28.579-7.28 ± 21.259
SecondaryPercent Change From Baseline in C5 Activation at Day 113

Blood samples were collected for analysis of C5 activation. Results are reported as percent change in both the complement classical pathway (CCP) activity response and the complement alternative pathway (CAP) activity response.

Time frame:
Baseline, Day 113
Reported as:
Mean · Percent Change
Percent Change From Baseline in C5 Activation at Day 113
Percent ChangeCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
CCP-1.66 ± 6.049-15.16 ± 22.7315.51 ± 10.839
CAP-17.54 ± 18.849-39.76 ± 10.214-5.90 ± 16.896
SecondaryNumber of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210

Blood samples were collected to evaluate antibody response through development of ADAs.

Time frame:
Baseline up to Day 309
Reported as:
Count of participants · Participants
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
ParticipantsCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210001

Adverse events

Collected over Baseline up to Day 309. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: ALXN1210 400 mg0/6 (0%)0/6 (0%)6/6 (100%)
Cohort 2: ALXN1210 800 mg0/6 (0%)0/6 (0%)6/6 (100%)
Placebo: Pooled0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventCohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: Pooled
HeadacheNervous system disorders4/63/62/4
NasopharyngitisInfections and infestations2/64/62/4
PharyngitisInfections and infestations0/64/60/4
Influenza like illnessGeneral disorders2/61/61/4
CoughRespiratory, thoracic and mediastinal disorders0/62/61/4
NauseaGastrointestinal disorders2/61/60/4
Viral upper respiratory tract infectionInfections and infestations2/62/60/4
Injection site painGeneral disorders0/60/61/4
AnxietyPsychiatric disorders0/60/61/4
PresyncopeNervous system disorders0/60/61/4

Baseline characteristics

Safety population: all participants who received at least 1 dose of ALXN1210 or placebo.

Age, Continuous
Age, Continuous(years)Cohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: PooledTotal
Mean28.7 ± 4.3235.2 ± 5.7833.5 ± 8.7032.3 ± 6.44
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: PooledTotal
Female0000
Male66416
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: PooledTotal
Not Hispanic or Latino66416
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: ALXN1210 400 mgCohort 2: ALXN1210 800 mgPlacebo: PooledTotal
Black or African American2013
White46313
08

Study locations

1 site
  • Clinical Trial Site
    London, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Clinical study report

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Sep 2016, 13 months.

Results were first posted in May 2023, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2022
First posted
Mar 21, 2022
StartActual
Jul 28, 2015
Primary completionActual
Sep 1, 2016
CompletionActual
Sep 1, 2016
Results first posted
May 9, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05288673
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Jul 28, 2015
Primary completion
Sep 1, 2016
Completion
Sep 1, 2016
Results posted
May 9, 2023
Last update
May 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion